Navigation Links
Questcor Pharmaceuticals Reports Strong Finish to 2011
Date:1/6/2012

  • Our reliance on Acthar for substantially all of our nets sales and profits;
  • Reductions in vials used per prescription resulting from changes in treatment regimens by physicians or patient compliance with physician recommendations;
  • The complex nature of our manufacturing process and the potential for supply disruptions or other business disruptions;
  • The lack of patent protection for Acthar; and the possible FDA approval and market introduction of competitive products;
  • Our ability to generate revenue from sales of Acthar to treat on-label indications associated with nephrotic syndrome, and our ability to develop other therapeutic uses for Acthar including SLE;
  • Research and development risks, including risks associated with Questcor's work in the area of nephrotic syndrome and potential work in the area of SLE, and our reliance on third-parties to conduct research and development and the ability of research and development to generate successful results;
  • Regulatory changes or other policy actions by governmental authorities and other third parties in connection with U.S. health care reform or efforts to reduce federal and state government deficits;
  • Our ability to receive high reimbursement levels from third party payers;
  • An increase in the proportion of our Acthar unit sales comprised of Medicaid-eligible patients and government entities;
  • Our ability to estimate reserves required for Acthar used by government entities and Medicaid-eligible patients and the impact that unforeseen invoicing of historical Medicaid prescriptions may have upon our results;
  • Our ability to operate within an industry that is highly regulated at both the Federal and state level;
  • Our ability to effectively manage our growth, including the expansion of our NS selling effort, and our reliance on key personnel;
  • The impact to Questcor's busine
    '/>"/>

SOURCE Questcor Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Questcor Pharmaceuticals to Present at the Piper Jaffray Healthcare Conference on November 30, 2011
2. Questcor Pharmaceuticals to Present at CLSAs 4th Annual AsiaUSA Forum on November 7, 2011
3. Questcor and Child Neurology Foundation Support the 3rd Annual Infantile Spasms (IS) Awareness Week
4. Questcor Reports Third Quarter Financial Results
5. Questcor to Report Third Quarter 2011 Earnings and Conduct Conference Call on October 25, 2011
6. Questcor Pharmaceuticals Announces Preliminary Operating Metrics for Third Quarter 2011
7. Questcor Pharmaceuticals to Present at the Jefferies Global Healthcare Conference on September 28, 2011
8. Questcor Provides Updated New Paid Prescription Trends
9. UPDATING and ADDING: Questcor Pharmaceuticals to Present at Upcoming Investor Conferences in September
10. Questcor Pharmaceuticals to Present at the Canaccord Genuity Growth Conference on August 11, 2011
11. Questcor to Report Second Quarter 2011 Earnings and Conduct Conference Call on July 26, 2011
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... , Jan. 15, 2014 The Cadence Fitness & ... Center by the Medical Fitness Association, a non-profit organization ... their full potential. The Cadence Fitness & Health Center ... suburbs and second in the Chicagoland area. ...
(Date:1/15/2014)... YORK , Jan. 15, 2014 ... report is available in its catalogue: ... for Advanced Drug Delivery Systems -- Focus ... STUDY OBJECTIVES ...
(Date:1/14/2014)... (Nasdaq: LMNX ) today announced that it expects ... Monday, February 3, 2014. A press release announcing the results ... (Logo: http://photos.prnewswire.com/prnh/20100104/LUMINEXLOGO ) Management will ... financial results for the fourth quarter and twelve months ended ...
Breaking Medicine Technology:Cadence Fitness & Health Center Certified as Medical Fitness Facility 2Cadence Fitness & Health Center Certified as Medical Fitness Facility 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 2Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 4Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 5Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 6Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 7Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 8Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 9Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 10Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 11Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 12Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 13Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 14Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 15Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 16Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 17Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 18Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014 2Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014 3
... March 20 Valor Medical, an emerging medical,device company ... human,implant of Neucrylate AN for treatment of cerebral aneurysms ... Tehran. The treatment was under the,guidance of a clinical ... Committee., Dr. Pakbaz stated that the patient,s aneurysm ...
... for more ... anticoagulation patients, INDIANAPOLIS, March ... meter training, equipment and supplies for all long-term,warfarin users who ... The change opens the door to greater convenience and,potentially fewer ...
Cached Medicine Technology:Medicare Announces Expanded Coverage for Warfarin Patients Monitoring Clotting Time at Home 2Medicare Announces Expanded Coverage for Warfarin Patients Monitoring Clotting Time at Home 3Medicare Announces Expanded Coverage for Warfarin Patients Monitoring Clotting Time at Home 4
(Date:7/9/2014)... French . By ... including brain structure and function, personality, life experiences and genetics, ... to develop binge drinking within the next two years. Impulsivity, ... as life events and a family history of drug use ... not the child had had a single drink at age ...
(Date:7/9/2014)... highlights, Brian Williams refreshing old school rap classics, and ... A University of Colorado Cancer Center study published in ... also allows researchers, journals, and health advocates to connect ... and prevention. , "No matter what field you,re in, ... around the world," says Chante Karimkhani, MD candidate in ...
(Date:7/9/2014)... retrospective study conducted by researchers at Tufts University School ... with intellectual and developmental disabilities, the likelihood of having ... care increased. The findings, published in the July/August issue ... improve interventions designed to address the oral health of ... the dental records of 107 patients at one of ...
(Date:7/9/2014)... study published in the scientific journal Nature Neuroscience ... researchers at Universit Laval, reveals that it is possible ... involves rekindling pain so that it can subsequently be ... alleviate chronic pain. , The researchers from the Faculty ... sant mentale de Qubec (IUSMQ) were inspired by previous ...
(Date:7/8/2014)... in Memory Restoration has been awarded up to $15 ... for a four -year project aiming to help brain-injured ... experts in neurosurgery, engineering, neurobiology, psychology and physics will ... prosthesis in the brain. , Memory is the process ... encode information, store it and retrieve it. Certain types ...
Breaking Medicine News(10 mins):Health News:What drives a child to abuse alcohol? 2Health News:Study of dermatology on YouTube shows new ways science reaches public 2Health News:Adults with special needs see gains, challenges with long term oral care 2Health News:Adults with special needs see gains, challenges with long term oral care 3Health News:Discovery of a new means to erase pain 2Health News:DARPA awards UCLA $15 million to restore lost memory 2Health News:DARPA awards UCLA $15 million to restore lost memory 3
... Will Set Key Industry Records, CARROLLTON, Texas, Sept. ... of medical imaging facilities, has,announced it has begun construction ... project, in Sherman, Texas, represents several,firsts of its kind. ... Texas, it is the first,joint venture between multiple hospitals ...
... and Wolf Haldenstein Obtain Third-Largest Settlement,in Securities Fraud ... PHILADELPHIA, Sept. 10 Judge Morris E.,Lasker of ... Massachusetts has,granted final approval of a $52.5 million ... against Sepracor Inc., a,Massachusetts-based pharmaceutical company (Nasdaq: ...
... provides evidence that noncoding RNAs and interactions between noncoding ... than was previously understood. The research, published by Cell ... Cell, may be useful for identifying tumor-specific signatures associated ... cells exhibit genetic alterations in oncogenes or tumor suppressor ...
... has been made by McMaster researchers about Fragile X ... one in 4,000 males and one in 6,000 females. ... associated with mental impairment. The affected gene (FMR1) leads ... the fragile X mental retardation protein (FMRP). , ...
... ... Conference, Majority of Students Polled Think Health Centers Need to Improve their ... ... 2007 Sexual Health Report Card, the second,annual ranking of sexual health resources at American colleges ...
... CITY, Calif., Sept. 10 Genomic,Health, Inc. (Nasdaq: ... studies that,support the use of quantitative real-time polymerase ... assay, for measuring the hormone,receptors, estrogen receptor (ER) ... A separate study identified multiple genes,including the 21 ...
Cached Medicine News:Health News:Fry Construction Selected for High-Profile Medical Imaging Project 2Health News:$52.5 Million Settlement Against Sepracor Inc. Approved 2Health News:Altered expression of ultraconserved noncoding RNAs linked to human leukemias and carcinomas 2Health News:Stem cell research produces a key discovery for Fragile X Syndrome 2Health News:Trojan(R) Ranks U.S. Colleges and Universities in Second Annual Sexual Health Report Card 2Health News:Trojan(R) Ranks U.S. Colleges and Universities in Second Annual Sexual Health Report Card 3Health News:Trojan(R) Ranks U.S. Colleges and Universities in Second Annual Sexual Health Report Card 4Health News:Trojan(R) Ranks U.S. Colleges and Universities in Second Annual Sexual Health Report Card 5Health News:Trojan(R) Ranks U.S. Colleges and Universities in Second Annual Sexual Health Report Card 6Health News:Trojan(R) Ranks U.S. Colleges and Universities in Second Annual Sexual Health Report Card 7Health News:Trojan(R) Ranks U.S. Colleges and Universities in Second Annual Sexual Health Report Card 8Health News:Trojan(R) Ranks U.S. Colleges and Universities in Second Annual Sexual Health Report Card 9Health News:Trojan(R) Ranks U.S. Colleges and Universities in Second Annual Sexual Health Report Card 10Health News:Trojan(R) Ranks U.S. Colleges and Universities in Second Annual Sexual Health Report Card 11Health News:Genomic Health Announces Multiple Studies on Oncotype DX(TM) Presented at 2007 American Society of Clinical Oncology (ASCO) Breast Cancer Symposium 2Health News:Genomic Health Announces Multiple Studies on Oncotype DX(TM) Presented at 2007 American Society of Clinical Oncology (ASCO) Breast Cancer Symposium 3Health News:Genomic Health Announces Multiple Studies on Oncotype DX(TM) Presented at 2007 American Society of Clinical Oncology (ASCO) Breast Cancer Symposium 4
Portex® Blue Line® cuffed endotracheal tubes come in a wide selection of sizes, each with a standard 15 mm ISO connector., ,Portex® Blue Line® endotracheal tubes are recognized world...
... PVC. 2 eyes, oral. Marked with ... X-ray opaque line. Graduated. Single use. ... reduce kinking of the tube by ... adapts to the anatomical situation at ...
... Ruschelit® PVC. Murphy eye-oral. High volume/low ... Oral Cuffed Single use. For improved ... of the tube by incorporating a ... cuff. Thermosensitive Ruschelit® PVC adapts to ...
Ruschelit® PVC. Siliconized. Stainless steel spiral reinforced. Murphy eye. High volume/low pressure cuff. Connector is permanently fixed into the tube. X-ray opaque. Graduated. Single use. Steri...
Medicine Products: